USA flag logo/image

An Official Website of the United States Government

Thermally Targeted Delivery of Therapeutic Peptides

Award Information

Agency:
Department of Health and Human Services
Branch:
N/A
Award ID:
93504
Program Year/Program:
2009 / SBIR
Agency Tracking Number:
CA135799
Solicitation Year:
N/A
Solicitation Topic Code:
N/A
Solicitation Number:
N/A
Small Business Information
Thermally Targeted Therapeutics, Incorporated
2500 NORTH STATE ST UMMC, Department of Biochemistry Jackson, MS 39216-4505
View profile »
Woman-Owned: No
Minority-Owned: No
HUBZone-Owned: No
 
Phase 1
Fiscal Year: 2009
Title: Thermally Targeted Delivery of Therapeutic Peptides
Agency: HHS
Contract: 1R43CA135799-01A2
Award Amount: $139,375.00
 

Abstract:

DESCRIPTION (provided by applicant): Current treatment of solid tumors is limited by normal tissue tolerance, inherent tumor resistance to radiation or chemotherapy, and toxicity from systemic administration of antineoplastic agents. The result is a narrow therapeutic index for most current chemotherapeutic agents. Our long term goal is to overcome these limitations by developing a targeted therapeutic approach for localized tumors that increases the specificity and efficacy of the therapy and reduces the c ytotoxicity in normal tissues. We have developed a thermally responsive polypeptide which inhibits cell cycle progression and proliferation of cancer cells in cell culture. The objective of the proposed research is to demonstrate that after systemic admini stration, these genetically engineered polypeptides can be targeted to the tumor site by applying local hyperthermia. This will results in accumulation of the agent in the tumor with subsequent inhibition of tumor growth. The amino acid sequence of the the rmally responsive polypeptides is based on elastin-like (ELP) biopolymers, which are soluble in aqueous solution below physiological temperature (37 oC), but aggregate when the temperature is raised above 41 oC. A cell-penetrating peptide, Bactenecin (Bac) is conjugated to the ELP to facilitate cell entry. To the Bac-ELP is added a peptide derived from the cyclin- dependent kinase inhibitor p21, which inhibits the cell cycle. Our preliminary in vitro results demonstrate a very significant effect of the Bac- ELP-p21 construct in Mat BIII rat mammary adenocarcinoma cells when compared to a non-thermally responsive control peptide. Our hypothesis is that intravenously delivered thermally responsive cell cycle inhibitory polypeptides are likely to be cleared unde r physiological conditions (37 oC). However, they will accumulate in breast tumors, where externally induced local heat (40-42 oC) will be applied. The accumulated polypeptides will inhibit the cell cycle and consequently inhibit proliferation of the cance r cells. In order to address this hypothesis, the following specific aims will be addressed: (1) measure the plasma kinetics and in vivo distribution of Bac-ELP-p21 in normal and neoplastic tissue and (2) evaluate the therapeutic efficacy of Bac-ELP-p21 in the treatment of breast tumor in rats through repeated administration of the agent coupled with and without local hyperthermia. The successful completion of the proposed research will provide the basis for a new technology that has a competitive advantage over existing/alternate technologies. These studies will provide the in vivo data necessary to move this therapy towards the translational stage of human therapeutics. Specific targeting of the proposed therapeutic polypeptides to solid tumors by local hy perthermia would increase efficacy of the cancer treatment and reduce the cytotoxicity in normal tissues, and it would provide an alternative means to substitute or augment present therapy for treatment of localized tumors. PUBLIC HEALTH RELEVANCE: Current treatment of solid tumors is limited because only a small fraction of the administered dose of drug reaches the tumor site while the rest of the drug is distributed throughout the body. This causes undesirable side effects to normal tissues when d rugs are used in the doses required to eradicate cancer cells. Our long term goal is to overcome this limitation by developing an approach that allows the therapeutics to be delivered specifically to the tumor site. This will increase the specificity of th e therapy and reduce the toxicity in normal tissues.

Principal Investigator:

Drazen Raucher
6019841510

Business Contact:

Draxen Raucher
Small Business Information at Submission:

THERMALLY TARGETED THERAPEUTICS
2500 NORTH STATE STREET UMMC, DEPARTMENT OF BIOCHEMISTRY JACKSON, MS 39216

EIN/Tax ID: 126280923
DUNS: N/A
Number of Employees: N/A
Woman-Owned: No
Minority-Owned: No
HUBZone-Owned: No